Cite
HARVARD Citation
Sabounjian, L. et al. (n.d.). A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease. Clinical pharmacology in drug development. 5 (4), pp. 314-325. [Online].